Phase III study of Efficacy, Safety and Pharmacokinetics of SJP-0129 in the Treatment for Patent Ductus Arteriosus

Trial Profile

Phase III study of Efficacy, Safety and Pharmacokinetics of SJP-0129 in the Treatment for Patent Ductus Arteriosus

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs SJP 0129 (Primary)
  • Indications Patent ductus arteriosus
  • Focus Therapeutic Use
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top